<s id="wsj_0463.1"> 31
1 	 0 	 N/N 	 1 	 Inc. Genentech
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Inc. said
6 	 3 	 NP[nb]/N 	 1 	 distributor the
6 	 4 	 N/N 	 1 	 distributor West
6 	 5 	 N/N 	 1 	 distributor German
6 	 7 	 (NP\NP)/NP 	 1 	 distributor of
6 	 12 	 ((S[dcl]\NP)/PP)/NP 	 1 	 distributor reached
11 	 7 	 (NP\NP)/NP 	 2 	 TPA of
11 	 8 	 NP[nb]/N 	 1 	 TPA its
11 	 9 	 N/N 	 1 	 TPA heart
11 	 10 	 N/N 	 1 	 TPA drug
12 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 reached said
16 	 12 	 ((S[dcl]\NP)/PP)/NP 	 3 	 agreement reached
16 	 13 	 NP[nb]/N 	 1 	 agreement a
16 	 14 	 N/N 	 1 	 agreement joint
16 	 15 	 N/N 	 1 	 agreement marketing
17 	 12 	 ((S[dcl]\NP)/PP)/NP 	 2 	 with reached
19 	 17 	 PP/NP 	 1 	 subsidiary with
19 	 18 	 NP[nb]/N 	 1 	 subsidiary a
19 	 20 	 (NP\NP)/NP 	 1 	 subsidiary of
22 	 20 	 (NP\NP)/NP 	 2 	 AG of
22 	 21 	 N/N 	 1 	 AG Hoechst
22 	 24 	 (NP\NP)/(S[dcl]\NP) 	 1 	 AG which
22 	 25 	 (S[dcl]\NP)/NP 	 1 	 AG makes <XB>
25 	 24 	 (NP\NP)/(S[dcl]\NP) 	 2 	 makes which
30 	 25 	 (S[dcl]\NP)/NP 	 2 	 streptokinase makes
30 	 26 	 NP[nb]/N 	 1 	 streptokinase the
30 	 27 	 N/N 	 1 	 streptokinase rival
30 	 28 	 N/N 	 1 	 streptokinase anti-clotting
30 	 29 	 N/N 	 1 	 streptokinase agent
<\s>
<s id="wsj_0463.2"> 38
2 	 0 	 NP[nb]/N 	 1 	 concern The
2 	 1 	 N/N 	 1 	 concern biotechnology
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 concern said
5 	 4 	 NP[nb]/N 	 1 	 agreement the
5 	 6 	 (NP\NP)/NP 	 1 	 agreement between
5 	 26 	 (S[dcl]\NP)/NP 	 1 	 agreement was
11 	 6 	 (NP\NP)/NP 	 2 	 distributor between
11 	 7 	 NP[nb]/N 	 1 	 distributor its
11 	 8 	 N/N 	 1 	 distributor longtime
11 	 9 	 N/N 	 1 	 distributor West
11 	 10 	 N/N 	 1 	 distributor German
13 	 14 	 (NP[nb]/N)\NP 	 2 	 Boehringer-Ingleheim 's
19 	 6 	 (NP\NP)/NP 	 2 	 subsidiary between
19 	 14 	 (NP[nb]/N)\NP 	 1 	 subsidiary 's
19 	 15 	 N/N 	 1 	 subsidiary Dr.
19 	 16 	 N/N 	 1 	 subsidiary Karl
19 	 17 	 N/N 	 1 	 subsidiary Thomae
19 	 18 	 N/N 	 1 	 subsidiary G.m.b.H.
22 	 23 	 (NP[nb]/N)\NP 	 2 	 Hoechst 's
25 	 6 	 (NP\NP)/NP 	 2 	 subsidiary between
25 	 23 	 (NP[nb]/N)\NP 	 1 	 subsidiary 's
25 	 24 	 N/N 	 1 	 subsidiary Behringwerke
26 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 was said
28 	 26 	 (S[dcl]\NP)/NP 	 2 	 attempt was
28 	 27 	 NP[nb]/N 	 1 	 attempt an
28 	 30 	 (S[b]\NP)/NP 	 1 	 attempt expand <XB>
30 	 29 	 (S[to]\NP)/(S[b]\NP) 	 2 	 expand to
32 	 30 	 (S[b]\NP)/NP 	 2 	 market expand
32 	 31 	 NP[nb]/N 	 1 	 market the
32 	 33 	 (NP\NP)/NP 	 1 	 market for
35 	 33 	 (NP\NP)/NP 	 2 	 drugs for
35 	 34 	 N/N 	 1 	 drugs blood-clot
35 	 36 	 (NP\NP)/NP 	 1 	 drugs in
37 	 36 	 (NP\NP)/NP 	 2 	 general in
<\s>
<s id="wsj_0463.3"> 21
2 	 0 	 NP[nb]/N 	 1 	 spokeswoman A
2 	 1 	 N/N 	 1 	 spokeswoman Genentech
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 spokeswoman said
5 	 4 	 NP[nb]/N 	 1 	 agreement the
5 	 6 	 (S[dcl]\NP)/S[for] 	 1 	 agreement calls
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 calls said
7 	 6 	 (S[dcl]\NP)/S[for] 	 2 	 for calls
8 	 7 	 (S[for]/(S[to]\NP))/NP 	 2 	 Hoechst for
8 	 10 	 (S[b]\NP)/NP 	 1 	 Hoechst promote <XB>
9 	 7 	 (S[for]/(S[to]\NP))/NP 	 1 	 to for
10 	 9 	 (S[to]\NP)/(S[b]\NP) 	 2 	 promote to
10 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 promote for
10 	 17 	 ((S\NP)\(S\NP))/NP 	 2 	 promote for
11 	 10 	 (S[b]\NP)/NP 	 2 	 TPA promote
14 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 patients for
14 	 13 	 N/N 	 1 	 patients heart
16 	 10 	 (S[b]\NP)/NP 	 2 	 streptokinase promote
20 	 17 	 ((S\NP)\(S\NP))/NP 	 3 	 purposes for
20 	 18 	 N/N 	 1 	 purposes other
20 	 19 	 N/N 	 1 	 purposes clot-reducing
<\s>
